ArticleChinese medical journal2026
m6A-modified circCD2AP suppressed ferroptosis in bladder cancer by upregulating FOXC1 to promote PARK7 transcriptional activity.
Article in Chinese medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- RNA m6A modification-regulated ferroptosis in cancer: mechanism and therapeutic potential.Frontiers in cell and developmental biology · 2026Review
- Mechanism and therapeutic prospects of ferroptosis regulation through m6A in cancer.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBladder cancer (BCa) is the most common genitourinary malignancy and causes substantial economic losses worldwide. Recent studies suggest overexpression of circCD2AP in BCa, but its mechanistic contributions to carcinogenesis and ferroptosis regulation remain unclear.
methodsFrom August 2021 to January 2024, 98 pairs of BCa and adjacent normal tissue samples were collected from the Third Xiangya Hospital, Central South University. Gene/protein expression, lipid reactive oxygen species (ROS) levels, and cell viability were analyzed. Interactions among circCD2AP /YTH domain-containing protein 1 (YTHDC1), circCD2AP, insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3), and IGF2BP3/forkhead box C1 (FOXC1) were validated, along with circCD2AP -IGF2BP3 colocalization. FOXC1 binding sites in the Parkinson's disease protein 7 (PARK7) promoter were mapped. N6-methyladenosine (m6A) modifications on circCD2AP were quantified via methylated RNA immunoprecipitation polymerase chain reaction.
resultscircCD2AP was significantly upregulated in BCa and positively correlated with PARK7 expression ( R2 = 0.1357, P = 0.0002). Patients with high circCD2AP expression showed poorer survival rates. CircCD2AP knockdown sensitized BCa cells to ferroptosis inducers (erastin and Ras-selective lethal small molecule 3). Methyltransferase-like 3 ( METTL3 ) knockdown inhibited circCD2AP m6A modification and relative expression. YTHDC1 mediated m6A-dependent cytoplasmic export of circCD2AP (2.8-fold increase). Besides, circCD2AP stabilized FOXC1 messenger RNA (mRNA), and FOXC1 bound the PARK7 promoter to enhance its expression. Knockdown of FOXC1 or PARK7 blocked the antiferroptotic effect of circCD2AP overexpression in BCa cells. Knockdown of METTL3 or circCD2AP reduced tumor burden in mice, decreasing both volume (approximately 48.3% or 56.4%) and weight (approximately 65.3% or 58.7%) through FOXC1/PARK7-mediated ferroptosis.
conclusionsMETTL3-mediated m6A modification drives circCD2AP overexpression, which is subsequently exported to the cytoplasm with enhanced efficiency mediated by YTHDC1. Cytoplasmic circCD2AP stabilizes FOXC1 mRNA, enabling FOXC1-dependent transcriptional activation of PARK7 . This axis suppresses ferroptosis and promotes BCa progression, revealing a novel therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.